Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ShanghaiTech Univ. GPR139 compound 15a
- Development stage
- Unknown
- Lead developer
- ShanghaiTech University
01
Overview
ShanghaiTech Univ. GPR139 compound 15a: sourced facts only. name: "Among them, compounds 15a (EC50 = 31.4 nM) and 20a (EC50 = 24.7 nM) showed potent agonist activity at GPR139 and good pharmacokinetic properties." [PMID:37830160]; target: "Among them, compounds 15a (EC50 = 31.4 nM) and 20a (EC50 = 24.7 nM) showed potent agonist activity at GPR139 and good pharmacokinetic properties." [PMID:37830160]; developer: "iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China." [PMID:37830160]
02
Targets
GPR139 (G protein-coupled receptor 139)
Beyond the preview
Go deeper on ShanghaiTech Univ. GPR139 compound 15a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ShanghaiTech Univ. GPR139 compound 15a.